Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?
- PMID: 35597590
- DOI: 10.1016/j.kint.2022.04.008
Should we consider calcimimetics as a therapeutic option for nephrotic syndrome?
Abstract
Calcimimetics allosterically increase the calcium ion sensitivity of the calcium-sensing receptor (CaSR). Using a CaSR knockdown in podocytes and a podocyte-specific CaSR knockout in mice, Mühlig et al. uncovered a stabilizing role for actin cytoskeleton and cell adhesion. Short-term alleviation of albuminuria and proteinuria was observed in 4 children treated with cinacalcet. Here we discuss the potential mechanisms whereby CaSR displays a favorable effect in podocytes and the context in which calcimimetics may alleviate nephrotic syndrome.
Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
The calcium-sensing receptor stabilizes podocyte function in proteinuric humans and mice.Kidney Int. 2022 Jun;101(6):1186-1199. doi: 10.1016/j.kint.2022.01.036. Epub 2022 Mar 7. Kidney Int. 2022. PMID: 35271934
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
